New Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific Meeting
October 11, 2023 08:00 ET
|
Daxor Corporation
Blood Volume Analysis (BVA) in 83-Patient Study Provided Highly Effective Guidance for Care of Heart Failure Patients Otherwise Unavailable Using Common Proxy Diagnostic Methods Oak Ridge, TN, Oct. ...
Daxor Corporation Awarded Support from the National Institutes of Health (NIH) Catalyze Preclinical Services Program
October 04, 2023 08:00 ET
|
Daxor Corporation
Support for Development of Daxor’s Non-Nuclear Tracer for Next Generation Blood Volume Analyzer Systems Aims to Deliver Gold Standard Accuracy with Increased Access, Ease of Use, and Frequency of...
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023
September 27, 2023 08:00 ET
|
Daxor Corporation
Daxor’s Blood Volume Technology Featured at Scientific Session Oak Ridge, TN, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement...
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL’23 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)
September 26, 2023 08:00 ET
|
Daxor Corporation
The Premier Event for The Cardiovascular Industry's Leading Network of Executives and Clinicians - Transforming Cardiovascular Care Through Sharing Best Practices and Organizational Performance...
Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients
September 11, 2023 12:00 ET
|
Daxor Corporation
Oak Ridge, TN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced that the National Institutes of Health...
Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023 09:15 ET
|
Daxor Corporation
Oak Ridge, TN, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
August 28, 2023 16:15 ET
|
Daxor Corporation
Oak Ridge, TN, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to...
Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023
August 28, 2023 16:05 ET
|
Daxor Corporation
Net Assets Increases to $30.4 Million From $29.0 Million Oak Ridge, TN, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100®
August 10, 2023 08:00 ET
|
Daxor Corporation
Researchers Call for Larger Clinical Trial Citing Outcomes from Study Oak Ridge, TN, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume...
JACC-HF Study Compares Daxor’s BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients
July 12, 2023 08:00 ET
|
Daxor Corporation
Volume and Pressure Measures are Complementary, Not Interchangeable Oak Ridge, TN, July 12, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement...